Continued Chemosensitivity to Cisplatin/Carboplatin in Ovarian Carcinoma Despite Treatment with Multiple Prior Platinum-Based Regimens
- 30 June 1997
- journal article
- case report
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 65 (3), 434-436
- https://doi.org/10.1006/gyno.1997.4708
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.Journal of Clinical Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerThe New England Journal of Medicine, 1996
- A Proposal to Use CA-125 to Evaluate Activity of New Antineoplastic Agents in Ovarian CancerGynecologic Oncology, 1993
- Cancer of the OvaryThe New England Journal of Medicine, 1993
- CA125 Measurement in Epithelial Ovarian Cancer: A 10-Year Anniversary of Clinical InvestigationGynecologic Oncology, 1993
- Serum CA 125 Level Allows Early Identification of Nonresponders during Induction ChemotherapyGynecologic Oncology, 1993
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990
- Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agentGynecologic Oncology, 1985
- Prolonged Disease-Free Survival in Hodgkin's Disease with MOPP Reinduction After First RelapseAnnals of Internal Medicine, 1979